PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1255285
PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1255285
Injectable Drug Devices and Products - 2023
“Injectable Drug Devices and Products - 2023” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injection devices. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Evolution in Therapeutic Care
Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver. For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market.
What You Will Learn:
- Provides detailed analysis of injectable drug products, drug delivery and device strategies, and product development factors.
- Assesses key markets, market dynamics and market demographics.
- Analyzes therapeutic demand drivers and evaluates injectable drug products in nine key therapeutic segments.
- Provides market data and forecasts.
- Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on drug product commercialization.
- Evaluates the impact of economic, technology, and regulatory factors.
Table of Contents
Executive Summary
- The Market Opportunity
- Delivery Market Dynamics
- The Economics of Injectable Drugs
- What's Driving the Growth in Injectable Devices?
- Prefilled Syringes Proliferating
- The Prefilled Syringe Supply Chain
- The Trend toward Self-Administration
- Shifting Demographics
- Innovation in Disposable Device Designs
- Proliferation of Biological Drugs
- Therapeutic Monoclonal Antibodies
- Risk Factors
- Injectable Drug Device Summaries
- Autoinjectors
Single Fixed Dose
- Molly (SHL Medical)
- Molly RNS (SHLMedical)
- Bertha (SHL Medical)
- Maggie (SHL Medical)
- Amber (SHL Medical)
- AutoJect 2 (Owen Mumford)
- SelfDose (West Pharmaceutical Services)
- DAI (SHL Medical)
- DI 2 (SHL medical)
- Flexi-Q PFS (Elcam Medical)
- Physioject (Becton DIckinson
- Intevia (Becton Dickinson)
Variable Dosing
- VSDI + NIT
- Ypsomed VarioJect
High Viscosity
- Rotaject Technology (SHL Medical)
- Reusable Pens
- Dual Chamber Pens
Commercial Pen Products
- Genotropin Pen
- Humatro-Pen/Humatro Pen 3
- Norditropin
- NordiPenmate
- Nutropin AQ Pen
- Omnitrope
- One.Click
- Lantus/Toujeo (Insulin Glargine)
- Diapen
- Gansulin Pen
- Flexpen (Novo Nordisk)
- Humalog Pen/KwikPen
- HumaPen Memoir
- HumaPen Luxura HD
- NovoPen (Novo Nordisk)
- SoloStar
- Byetta Pen
- Bydureon
- SymlinPen
- Saxenda (Liraglutide)
- Tanzeum (Abliglutide)
- Trulicity (Dulaglutide)
- Victoza (Liraglutide)
Parathyroid Hormone
- Forteo Pen
- Preotact/Preos
- Natpara
Reproductive Hormones
- Follistim/Puregon Pen
- Gonal-f
Wearable Devices - Analysis and Assessments
- Libertas (Becton Dickinson)
- SmartDose (West Pharmaceuticals)
- Neulasta OnPro Injector (Insulet/Amgen)
- YpsoDose (Ypsomed)
- Electronic Semi-disposable
- eLVD Patch Pump (Elcam)
- Ypsomed/Ypsomed 2.25)
- Flexi-Q HV (Elcam Medical)
Dual Chamber
- SDI MIX +NIT (SHL Medical)
Wirelessly Enabled Autoinjectors
- BETACONNECT (Bayer)
- RebiSmart (Merck Serono)
Selected Product Specific Autoinjectors
- Alsuma/Sumatriptan Autoinjector
- Sumatriptan (Dr. Reddy's)
- Rebif/Rebidose (Merck Serono)
- Aimovig (Amgen/Novartis)
- Enbrel Mini AutoTouch (Amgen)
- Pegasys Proclick (Genentech/Roche)
- Otrexup (Antares Pharma)
- Evzio (Kaleo)
Autoinjector Device Design Factors
- Material Selection Issues
- Part Counts and Device Cost
- Safety Features
- Needle Insertion Depth
- Failsafe Activation
- Dose Inspection/Injection Confirmation
Market Factors
- Lyophilized Drugs/Reconstitution
- Human Engineering/Ergonomics
Pen Injectors
- Pen Injector Design Selection Factors
- Standardized Pen Platforms
- Haselmeier
- Becton Dickinson
- Owen Mumford
- Autoject2
- Ypsomed
- SHL Medical
- Custom Pen Designs
Emerging Technology
- Wireless Data
Injectable Drug Market Analysis and Forecasts
- Autoimmune Diseases
- Rheumatoid Arthritis
- Psoriasis
- Multiple Sclerosis
- Hematopoietics
- Hormones
- Osteoporosis
- Fertility
Market Factors
- Regulatory Issues
- Device Branding
- Patient Adherence and Ease of Use
- Healthcare Economics
Company Profiles
